Pfizer Inc.'s Aromasin can cut the risk of developing breast cancer down by more than half. This is not suggested for women at average risk of breast cancer. For women who are at a higher risk due to other reasons, such as gene mutations, are the target subjects. They're prior choices of prevention had adverse side effects, such as, blood clots and uterine cancer. During the study, subjects on the drug showed a 65% risk reduction. Despite the drug's postive results so far, nothing is guaranteed. However, this is important research being done considering that breast cancer diagnoses are on the rise.



-Associated Press